Retinal nerve fiber layer thickness predicts CSF amyloid/tau before cognitive decline by S. Asanad et al.
RESEARCH ARTICLE
Retinal nerve fiber layer thickness predicts
CSF amyloid/tau before cognitive decline
Samuel Asanad1,2, Michele Fantini1,2,3, William Sultan1, Marco Nassisi1,4, Christian
M. Felix2, Jessica Wu2, Rustum Karanjia1,2,5,6, Fred N. Ross-Cisneros1, Abhay P. Sagare7,
Berislav V. Zlokovic7, Helena C. Chui8, Janice M. Pogoda9, Xianghong Arakaki10, Alfred
N. Fonteh10, Alfredo A. Sadun A. A.1,2‡, Michael G. HarringtonID10*‡
1 Doheny Eye Institute, Los Angeles, CA, United States of America, 2 Department of Ophthalmology, David
Geffen School of Medicine at UCLA, Los Angeles, CA, United States of America, 3 Department of Medicine,
Ophthalmology, University of Udine, Udine, Italy, 4 Department of Clinical Sciences and Community Health,
Ophthalmological Unit, IRCCS-CàGranda Foundation—Ospedale Maggiore Policlinico, University of Milan,
Milan, Italy, 5 Department of Ophthalmology, University of Ottawa, Ottawa, Ontario, Canada, 6 Ottawa
Hospital Research Institute, Ottawa, Ontario, Canada, 7 Department of Physiology and Neuroscience, Zilkha
Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, United
States of America, 8 Department of Neurology, University of Southern California, Los Angeles, CA, United
States of America, 9 Cipher Biostatistics & Reporting, Reno, NV, United States of America, 10 Huntington
Medical Research Institutes, Pasadena, CA, United States of America
‡ These authors are joint senior authors on this work.
* michael.harrington@hmri.org
Abstract
Background
Alzheimer’s disease (AD) pathology precedes symptoms and its detection can identify at-
risk individuals who may benefit from early treatment. Since the retinal nerve fiber layer
(RNFL) is depleted in established AD, we tested whether its thickness can predict whether
cognitively healthy (CH) individuals have a normal or pathological cerebrospinal fluid (CSF)
Aß42 (A) and tau (T) ratio.
Methods
As part of an ongoing longitudinal study, we enrolled CH individuals, excluding those with
cognitive impairment and significant ocular pathology. We classified the CH group into two
sub-groups, normal (CH-NAT, n = 16) or pathological (CH-PAT, n = 27), using a logistic
regression model from the CSF AT ratio that identified >85% of patients with a clinically
probable AD diagnosis. Spectral-domain optical coherence tomography (OCT) was
acquired for RNFL, ganglion cell-inner plexiform layer (GC-IPL), and macular thickness.
Group differences were tested using mixed model repeated measures and a classification
model derived using multiple logistic regression.
Results
Mean age (± standard deviation) in the CH-PAT group (n = 27; 75.2 ± 8.4 years) was similar
(p = 0.50) to the CH-NAT group (n = 16; 74.1 ± 7.9 years). Mean RNFL (standard error) was
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thinner in the CH-PAT group by 9.8 (2.7) μm; p < 0.001. RNFL thickness classified CH-NAT
vs. CH-PAT with 87% sensitivity and 56.3% specificity.
Conclusions
Our retinal data predict which individuals have CSF biomarkers of AD pathology before cog-
nitive deficits are detectable with 87% sensitivity. Such results from easy-to-acquire, objec-
tive and non-invasive measurements of the RNFL merit further study of OCT technology to
monitor or screen for early AD pathology.
Introduction
Alzheimer’s disease (AD) is the leading cause of dementia and one of the most expensive dis-
eases in America at a total cost of $290 billion in 2019 [1–3]. Over 26 million people are cur-
rently affected by AD worldwide, however this prevalence is estimated to quadruple by 2050.
Widespread screening approaches are urgently needed to diagnose early disease stages to allow
therapy trials before symptomatic decline [4,5].
In considering accessible and noninvasive screening approaches, ophthalmologic impair-
ments including contrast sensitivity, color recognition, and motion perception have been
reported in early stages of dementia, even prior to manifesting as a clear diagnosis of AD [6–
12]. These visual dysfunctions in AD have been associated with degeneration of the optic
nerve and retina, developmental outgrowths of the brain [13–15], since cortical deficits alone
do not explain these visual deficits [11,12,16,17]. The first ocular manifestations of AD were
shown by our laboratory, where the optic nerves of postmortem tissue exhibited diffuse axonal
degeneration [18,19]. More recently, hallmark pathologies of neurodegeneration typical for
AD in the brain have also been suggested in the retina. We previously demonstrated amyloid
β-protein (Aβ) accumulation inside and around melanopsin-containing RGCs (mRGCs) in
AD, possibly explaining circadian rhythm disturbances seen in these patients [20]. Additional
studies have identified Aβ plaque pathology in postmortem retinas of AD patients as well as in
early-stage disease [1,20–24]. Following the advent of optical coherence tomography (OCT),
in vivo studies have revealed significant retinal thinning [16, 25–28]; however, the clinical util-
ity of the retina as a biomarker for early AD has not been established [29–34].
The pre-symptomatic phase of AD is recognized in cognitively healthy (CH) individuals
having AD pathology many years prior to symptom onset, based on altered amyloid and tau
biomarkers detected using positron emission tomography (PET) or cerebrospinal fluid (CSF)
analysis [35,36]. For example, our laboratory recently demonstrated that pre-symptomatic AD
can be detected more sensitively and specifically by the CSF Aβ42/Tau ratio relative to the con-
centration of these biomarkers independently [37, 38]. The purpose of this study was to inves-
tigate whether retinal thickness can predict whether CH individuals have a normal or
pathological Aß42/Tau ratio.
Materials & methods
Human participants
The Institutional Review Boards of both the Huntington Medical Research Institutes (HMRI),
Pasadena (IRB #33797) and the University of California Los Angeles (IRB #17001645)
approved the protocol and consent forms for this study, which was conducted and performed
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in compliance with the ethical standards set out in the Declaration of Helsinki. Prior to enroll-
ment, all study participants gave written, informed consent. Clinical and CSF studies were per-
formed at HMRI, and ophthalmology assessments were conducted at the Doheny Eye Center,
Department of Neuro-ophthalmology, Pasadena, CA.
Participants over 60 years of age were recruited locally at HMRI for aging research if they
had no cognitive impairment after medical and neuropsychological assessment, using the Uni-
form Data Set criteria of the National Alzheimer’s Coordinating Center (https://www.alz.
washington.edu/WEB/npsych_means.html) and after consensus clinical conference. CSF
Aß42/Tau ratios were determined from lumbar fluid as described [37]. MSD assay (catalog no.
K15199G, MSD, Rockville, MD) was used to determine CSF levels of Aβ42. MSD assay (catalog
no. K15121G, MSD, Rockville, MD) was used to determine CSF levels of total tau. We used a
logistic regression cutoff for the CSF Aß42/Tau ratio that correctly classified more than 85% of
probable AD patients to identify two separate cohorts of the CH participants: those with Nor-
mal Aß42/Tau ratio (“CH-NAT”), or those with Pathological Aß42/Tau ratio (“CH-PAT”). We
thus defined that CH-PAT individuals had preclinical AD.
Ophthalmic examination included tonometry, assessment of best-corrected visual acuity
(BCVA), slit lamp examination of the anterior segment, and dilated fundus examination for all
participants. Exclusion criteria for all groups were: BCVA < 20/50; refractive error > ± 5
spherical equivalent; poor image quality defined by an image signal less than 6 due to severe
cataracts or unstable fixation; intraocular pressure (IOP) > 20mm Hg; pre-existing macular
pathologies such as age-related macular degeneration, epiretinal membrane or macular hole;
other retinopathies such as retinal vascular occlusion or retinal dystrophy; pre-existing ocular
diseases such as glaucoma, optic neuropathy or uveitis; previous intraocular surgery or laser
treatment except for cataract surgery performed at least 12 months prior to enrolment; pene-
trating ocular trauma; current active smoking status; and history or evidence of other neuro-
logical or psychiatric disorders, diabetes mellitus, poorly controlled systemic arterial
hypertension defined by systolic > 150 and diastolic > 90, cardiovascular diseases, renal fail-
ure, substance abuse in the past 5 years, systemic corticosteroid use exceeding 6 months, and
systemic autoimmune conditions with associated optic neuropathies.
Instrumentation and procedures
RNFL, RGC-IPL, and full macular thicknesses were measured for all participants using spec-
tral-domain OCT (Cirrus SD-OCT, software v 6.0; Carl Zeiss Meditec). Scans were all acquired
using the protocols for Optic Disc Cube 200 x 200 and the Macular Cube 512 x 128 in both
eyes with pupil dilation. Following proper seating and alignment of each individual, the iris
was brought into view using the mouse-driven alignment system, and the ophthalmoscopic
image was focused. To acquire the Optic Disc Cube as seen in Fig 1A, the optic nerve head was
centered on the live image, and centering and enhancement were optimized. After launching
the scanning process, the instrument’s 840 nm wavelength laser beam generated a cube of data
measuring 6 mm x 6 mm after scanning a series of 200 B-scans with 200 A-scans per B-scan
(40,000 points) in 1.5 seconds (27,000 A-scans/sec). Cirrus SD-OCT algorithms were used to
find the optic disc with automatic placement of a calculation circle measuring 3.46 mm in
diameter symmetrically around it. Layerseeking algorithms were used to find the RNFL inner
(anterior) boundary and the RNFL outer (posterior) boundary for the entire cube except the
optic disc. The system extracted 256 A-scan samples from the data cube along the path of the
calculation circle.
With respect to acquiring the Macular Cube, participants fixated on the central target. The
ganglion cell analysis algorithm detected and measured the thickness of the macular RGC-IPL
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within a 14.13-mm2 elliptical annulus area centered on the fovea (Fig 1B). The ganglion cell
analysis algorithm processed data from 3-dimensional volume scans and measured the thick-
ness of the macular RGC-IPL. The average, minimum, and 6 sectoral (superotemporal, supe-
rior, superonasal, inferonasal, inferior, and inferotemporal) RGC-IPL thicknesses were
measured from centering the elliptical annulus on the fovea (Fig 1B). Retinal thickness maps
of the total macular region were acquired using the macular cube scan within a 6 × 6-mm2 cir-
cular area centered on the fovea. Measurements were averaged over 9-retinal subfields, as
defined by the Early Treatment Diabetic Retinopathy Study (ETDRS) (Fig 1C). A published,
detailed description of this algorithm and how it operates is available for reference [39]. The
built-in SD-OCT eye-tracking system provided reproducible measurements with a coefficient
of variation of 0.5% [40].
An experienced operator captured all images. Individual scan volumes were reviewed for
segmentation errors. Scans with significant motion artifacts, segmentation errors, or signal
strength values less than 6 were excluded from analysis. To maximize the reflective signal,
polarization was optimized and the scan with the best centration of the optic disc was consis-
tently selected. The thicknesses of the three regions were then compared between the two
cohorts and correlated with their CSF levels of Aß42, Tau, and Aß42/Tau ratio.
Statistical methods
Comparisons between groups on retinal thickness were made using mixed model repeated
measures with unstructured covariance. Group (CH-NAT, CH-PAT), layer (RNFL, GC-IPL,
macula), side (OD, OS), and region (S, N, I, T) were fixed effects. Error degrees of freedom
was calculated using the Kenward-Rogers approximation. Model assumptions were checked
using Q-Q and scatter plots of residuals. Model-based least-squares (LS) means, standard
errors, and p-values for tests of differences in LS means are reported.
Multivariable logistic regression was used to predict CH-PAT group membership (depen-
dent variable) based on retinal thickness (independent variables). Only subjects with all data
points available (retinal thickness for all 3 layers, both sides, and all 4 regions) were included.
Correlations between pairs of independent variables were assessed to minimize collinearity;
for highly correlated pairs (r> 0.7), only the variable with the strongest association with group
was retained as a candidate predictor. Independently significant predictors constituted the
final model. A cutoff value for the probability that a given subject is CH-PAT was selected
based on sensitivity and specificity, and the cutoff probability was entered into the left side of
the final model equation to derive a decision boundary.
Statistical significance was defined as p< 0.05, two-sided. As an exploratory study, no
adjustments were made for multiplicity. Analyses were done using SAS v9.4 (SAS Institute,
Inc., Cary NC).
Results
Twenty-seven participants were classified as CH-PAT (mean age ± standard deviation
75.2 ± 8.4 years; 48% female) and 16 as CH-NAT (mean age 74.1 ± 7.4 years; 56% female).
Fig 1. Illustrates optical coherence tomography imaging of the peripapillary and macular areas. (A) The
thicknesses of the 4 retinal nerve fiber layer quadrants (temporal, superior, nasal, inferior); (B) ganglion cell-inner
plexiform layer sectors (superior-temporal, superior, superior-nasal, inferior-nasal, inferior, inferior-temporal; (C)
macular full-thickness sectors (center, inner-superior, outer-superior, inner-inferior, outer-inferior, inner-temporal,
outer-temporal, inner-nasal, outer-nasal) were measured using peripapillary and macular circular scans centered on
the disc and on the fovea, respectively).
https://doi.org/10.1371/journal.pone.0232785.g001
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There were no significant group differences at the macular or GC-IPL locations in the OCT
data (S1 Table). However, mean RNFL was thinner (p = 0.0009) in the CH-PAT than
CH-NAT group, as summarized in Table 1. Fig 2 displays the 10μm difference between these
groups. The difference between groups in mean RNFL thinning was significant at the nasal
location (S2 Table). The CSF Aß42/ Tau ratio was more correlated with RNFL thinning com-
pared to individual biomarkers, however examination of the roles of each independent bio-
marker displayed in the scatter plots of S1 Fig suggests that the CSF total Tau levels correlate
more with RNFL thinning than Aß42.
Logistic regression was used to predict CH-PAT from S, N, I, T regions for each of OD and
OS. The best model included only OD_T and OD_N as predictors (all of the OS measurements
were highly correlated with their OD counterparts, but not nearly as predictive). This required
omitting from the analysis participants with any missing data of the 8 possible predictors,
which resulted in the exclusion of 4 individuals. After determining the best model (OD_T and
OD_N), a cutoff for predicted event probability was chosen such that sensitivity was at least
85% and specificity was maximized. The selected cutoff of 0.46 yielded 87% sensitivity and
56% specificity (AUC = 0.83).
Discussion
These results extend the findings of optic neuropathy being a common feature in AD as first
demonstrated by our laboratory over 30 years ago [19]. More recently, the availability of
Table 1. Retinal thickness by layer.
Layer CH-NAT (N = 16 subjects) CH-PAT (N = 27 subjects)
p-value
RNFL
n 128 192
Mean (SD) 88.76 (24.290) 84.24 (24.112)
LS Mean (SE)1 93.27 (2.201) 83.46 (1.812) 0.0009
Median 92.75 86.00
IQR 65.00 - 108.00 61.25 - 102.75
Range 48.0 - 135.0 41.0 - 133.0
GC-IPL
n 186 306
Mean (SD) 74.42 (6.316) 73.09 (6.693)
LS Mean (SE)1 75.06 (1.312) 73.13 (1.068) 0.22
Median 74.50 73.50
IQR 70.00 - 78.50 69.00 - 77.00
Range 59.0 - 93.0 52.0 - 94.0
Macula
n 279 459
Mean (SD) 294.48 (29.663) 287.27 (28.936)
LS Mean (SE)1 291.67 (4.110) 288.97 (3.191) 0.60
Median 293.50 290.00
IQR 270.00 - 318.00 264.00 - 309.50
Range 232.5 - 383.5 211.0 - 355.0
Abbreviations: GC-IPL, ganglion cell-inner plexiform layer; IQR, interquartile range; LS, least-squares; n, number of measurements; RNFL, retinal nerve fiber layer; SD,
standard deviation; SE, standard error.
1 Adjusted for side (OD, OS) and region (S, I, T, N).
https://doi.org/10.1371/journal.pone.0232785.t001
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sensitive and reliable retinal imaging techniques has revealed a number of retinal abnormali-
ties in earlier stages of AD [28]. The major finding from this study is that RNFL thickness mea-
sure by OCT was able to predict the biochemical class of CH-NAT vs. CH-PAT in cognitively
healthy, older individuals with high sensitivity (Fig 2 and Table 2). This is the first study to pre-
dict pre-symptomatic AD pathology with high sensitivity using non-invasive technology and
provides an opportunity to encourage widespread screening.
We assessed retinal pathology in relation to both CSF Aß and Tau. When analyzed individ-
ually, CSF Tau was more associated with RNFL thickness relative to amyloid. Notably, this
observed relationship between CSF protein levels and the retina is similar to that observed
when CSF Aß is known to be inversely correlated with Aß load and neuropathology in the
brain, whereas CSF Tau is known to be directly correlated. More importantly, the combined
Fig 2. Depicts least-squares mean (95% CI) retinal nerve fiber layer (RNFL) thickness adjusted for side and region between cognitively healthy controls (blue) and
preclinical AD participants (red).
https://doi.org/10.1371/journal.pone.0232785.g002
Table 2. Logistic regression model for the probability of CH-PAT based on retinal thickness in the retinal nerve fiber layer.
Parameter Coefficient (SE) Odds Ratio (95% CI) p-value
Intercept 15.62 (5.120) -- -- --
OD Side, Region N -0.10 (0.041) 0.91 (0.84, 0.98) 0.02
OD Side, Region T -0.14 (0.052) 0.87 (0.79, 0.97) 0.008
https://doi.org/10.1371/journal.pone.0232785.t002
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ratio of CSF Aß and Tau has been shown to predict AD neuropathology with high accuracy,
outweighing the performance of these proteins individually [41]. Our findings are further sup-
ported by recent studies illustrating the role of Tau dysfunction in pre-symptomatic AD,
whereby Tau pathology of the retina may precede pathology of the brain and cognitive loss
[42]. The present results on the retina support our previous findings in regard to the advan-
tages of using an index for the ratio of two biomarkers for predicting AD pathology [37], sug-
gesting that both amyloid and Tau likely contribute, independently, to retinal pathology.
We found significant RNFL thinning in pre-symptomatic AD participants. Studies in
patients with symptomatic cognitive impairment including AD have also shown RNFL thin-
ning, which significantly correlated with visual function and cognitive deficits [43–52]. Studies
have also illustrated retinal atrophy of the macular region. Cunha et al. reported thinning of
the GC-IPL and macular full-thickness reduction in addition peripapillary RNFL loss [53].
The group found significant correlations between cognitive function testing and retinal thick-
ness in both the peripapillary and macular regions [53]. Additional studies conducted by Mar-
tin et al. investigated retinal layer thickness changes in relation to disease duration and severity
[25]. Notably, RNFL thinning in AD occurred early while RGCL as well as outer retinal layer
thinning occurred later [25]. This progressive pattern of RNFL loss followed by RGCL loss is
consistent with previous studies conducted by our laboratory using postmortem histopathol-
ogy [54]. These tissues were histopathologically confirmed for Aβ deposition and were derived
from patients who were neuropathologically confirmed for severe AD. In addition, retinal
layer thickness profiles matched the distribution of retinal Aβ deposits in these tissues, as pre-
viously demonstrated by our laboratory and others [20, 21,23,54–56].
Our study also showed thinning of the GC-IPL and macular full-thickness regions, though
these were not statistically significant. Longitudinal studies conducted by Santos et al. have
reported similar findings [57]. Specifically, Santos and colleagues found significant thinning
primarily of the RNFL in preclinical AD [57]. Macular thinning involving the inner plexiform
and outer nuclear layers were also observed. However, these thickness changes were reportedly
attributed to age-related decline, as expected over the timespan of the study. Notably, only the
RNFL significantly correlated with neocortical amyloid load as measured by positron emission
tomography [57]. These results corroborate our retinal thickness findings and support the
premise that nerve fiber layer axonal loss as measured by OCT precedes symptomatic cognitive
decline.
Retinal thickness changes have also been investigated in mild cognitive impairment (MCI).
Previous OCT studies have illustrated retinal thinning in MCI, although less severe relative to
AD [18,30,34,46,50,58–60]. These findings might suggest MCI as a transitional stage between
normal cognitive function and dementia. Notably, however, prior studies have been variable
in their results. Ascaso et al. and Oktem et al. reported significant RNFL thinning in MCI
[34,50], whereas Almeida et al. found significant GC-IPL thinning [61] or no significant retinal
thinning [62,63]. In addition, Ascaso et al. and Oktem et al. reported a significant correlation
between RNFL thickness and Mini-Mental State Examination (MMSE) scores in MCI [34,50],
while Almeida et al. observed a significant correlation between GC-IPL thickness and MMSE
scores [61]. In turn, retinal thickness findings in MCI have been controversial and the utility
of the retina as a marker of disease conversion from MCI to AD remains inconclusive. These
discrepant findings between studies may be attributed to confounding factors including seg-
mentation algorithms, variability between OCT devices, and the diagnostic criteria for AD and
MCI [28,64,65]. Researchers have largely relied on the MMSE as a screening measure of gen-
eral cognitive function. Importantly, however, this test has several reported psychometric limi-
tations and may not always be a reliable cognitive marker [66]. MCI is a complex,
PLOS ONE Retinal nerve fiber layer thickness predicts CSF amyloid/tau before cognitive decline
PLOS ONE | https://doi.org/10.1371/journal.pone.0232785 May 29, 2020 8 / 13
heterogeneous stage of cognitive decline. Patients may not progress to AD, may revert back to
normal cognitive health, or may advance to non-AD dementia [67].
Our present study on early AD pathology differed in two ways that are important because
the pathology is known to start many years before symptoms. Our two test groups were both
cognitively healthy as defined after detailed neuropsychiatric testing and were biochemically
differentiated based on cutoff levels that are established in AD for CSF Aß42 and total tau
biomarkers.
Previous reports have evaluated retinal thickness changes in preclinical AD using OCT.
Few have examined CSF protein levels, although exclusively with respect to Aß, and have
found little or no correlation between OCT findings and neurologic parameters [43, 68]. Nota-
bly, however, Tau burden has been shown to be more consistent with level of cognitive
impairment in AD than cerebral Aß accumulation [44, 69]. The current article analyzes, for
the first time, retinal morphology in relation to both CSF Aß and Tau CSF levels. Strengths of
the current study include not only rigorous selection of pre-symptomatic participants, but also
using a cutoff for CSF Aß /Tau ratios that was previously demonstrated by our laboratory to
correctly predict 85% of participants with AD.
Limitations of this study are those that would be expected in an exploratory approach. The
statistical models require validation, and the findings need to be replicated and applied to dif-
ferent populations to assess both neurological and ophthalmological disease, physiological,
and cultural/ethnic specificity. Nevertheless, the present article represents the largest study of
RNFL as measured by OCT in preclinical AD. Our investigation was also cross-sectional in
nature. Proper characterization of disease natural history requires a long-term longitudinal fol-
low-up study. Therefore, we intend to use these results as baseline values for future longitudi-
nal studies. Further investigation is necessary to precisely elucidate the mechanism of retinal
pathology observed in these cohorts. Sensitive retinal biomarkers may be advantageous given
their cost and time efficiency in addition to their non-invasiveness and high level of accessibil-
ity [44]. Therefore, the purpose of our study was to investigate retinal nerve fiber thickness as a
potential screening tool for individuals at risk for AD, thereby maximizing sensitivity. Our lab-
oratory is in the process of deriving a balanced cut-off that maximizes sensitivity in addition to
specificity. OCT measurements have the immediate potential to allow rapid data acquisition in
studies of AD patients or those at risk for AD with the objective of building a large database of
RNFL thickness in different AD patient populations.
Conclusions
We report that RNFL thickness of cognitively healthy older individuals predicts CSF amyloid/
tau, the gold standard biomarker of AD pathology, with 87% sensitivity in a cross-sectional
study. Because OCT is widely available, we think this data may inspire a large community
health opportunity to evaluate screening for individuals at risk for AD.
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